Strategic Funding Leverage OnCusp’s strong Series A financing of $100M with prominent investors to pursue co-development and milestone-based partnerships with oncology asset creators and contract development organizations seeking funding validation and collaboration opportunities.

Leadership Additions Target outreach to pharma partners and academic alliances highlighting recent C-suite appointments (CFO Anthony Kim and CMO Dimitry Nuyten) to signal strengthened governance, financial discipline, and clinical development leadership for joint programs and co-commercialization prospects.

Clinical Focus Position to collaborate around the company’s cdh6-directed antibody-drug conjugate CUSP06 and related oncology assets, aligning with partners aiming to accelerate first-in-human to early-phase trials in platinum-refractory ovarian cancer and other solid tumors.

Geographic & Market Readiness Highlight Princeton, NJ headquarters and global partnerships as a launchpad for US-EU translational collaborations, licensing deals, and regional manufacturing partnerships to scale clinical-grade production and distribution for oncology assets.

Investor & Portfolio Synergy Propose joint-investment or venture collaboration opportunities with Novo Holdings, OrbiMed, and F-Prime Capital-affiliated boards to piggyback on their networks for new asset acquisition, portfolio diversification, and strategic exits.